BR112015021271A2 - Agonistas muscarínicos - Google Patents

Agonistas muscarínicos

Info

Publication number
BR112015021271A2
BR112015021271A2 BR112015021271A BR112015021271A BR112015021271A2 BR 112015021271 A2 BR112015021271 A2 BR 112015021271A2 BR 112015021271 A BR112015021271 A BR 112015021271A BR 112015021271 A BR112015021271 A BR 112015021271A BR 112015021271 A2 BR112015021271 A2 BR 112015021271A2
Authority
BR
Brazil
Prior art keywords
muscarinic agonists
muscarinic
agonists
cholinergics
disease
Prior art date
Application number
BR112015021271A
Other languages
English (en)
Inventor
S Burstein Ethan
Eskildsen Jorgen
Olsson Roger
M Luhrs Lauren
A Wheeler Larry
W Gil Daniel
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of BR112015021271A2 publication Critical patent/BR112015021271A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

AGONISTAS MUSCARÍNICOS. A presente invenção refere-se aos compostos de fórmula e métodos para o tratamento de uma doença ou problemas de saúde nas quais a modificação de colinérgicos, especialmente receptores de atividade muscarínicos, tem um efeito benéfico.
BR112015021271A 2013-03-15 2014-03-14 Agonistas muscarínicos BR112015021271A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790364P 2013-03-15 2013-03-15
PCT/US2014/026998 WO2014152144A1 (en) 2013-03-15 2014-03-14 Muscarinic agonists

Publications (1)

Publication Number Publication Date
BR112015021271A2 true BR112015021271A2 (pt) 2017-08-22

Family

ID=50439523

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021271A BR112015021271A2 (pt) 2013-03-15 2014-03-14 Agonistas muscarínicos

Country Status (13)

Country Link
US (1) US9670209B2 (pt)
EP (1) EP2976079A1 (pt)
JP (1) JP2016513677A (pt)
KR (1) KR20150143439A (pt)
CN (1) CN105120865A (pt)
AU (1) AU2014240139A1 (pt)
BR (1) BR112015021271A2 (pt)
CA (1) CA2903276A1 (pt)
IL (1) IL241001A0 (pt)
MX (1) MX2015012043A (pt)
RU (1) RU2015144155A (pt)
TW (1) TW201446761A (pt)
WO (1) WO2014152144A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150143439A (ko) 2013-03-15 2015-12-23 알레간 인코포레이티드 무스카린성 효능제
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN109219594B (zh) 2016-03-31 2022-10-11 英克特诺治疗公司 吲哚啉类似物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707798A (en) 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
JPH10152470A (ja) * 1996-09-25 1998-06-09 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
EP1535912A1 (en) * 2000-04-28 2005-06-01 Arcadia Pharmaceuticals Inc. Muscarinic agonists
JP4119126B2 (ja) 2000-04-28 2008-07-16 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリン性アゴニスト
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
EP1613321A2 (en) * 2003-03-28 2006-01-11 Acadia Pharmaceuticals Inc. Muscarinic m1 receptor agonists for pain management
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
KR20150143439A (ko) 2013-03-15 2015-12-23 알레간 인코포레이티드 무스카린성 효능제

Also Published As

Publication number Publication date
US20160039819A1 (en) 2016-02-11
EP2976079A1 (en) 2016-01-27
AU2014240139A1 (en) 2015-09-17
MX2015012043A (es) 2016-03-17
IL241001A0 (en) 2015-11-30
TW201446761A (zh) 2014-12-16
CN105120865A (zh) 2015-12-02
CA2903276A1 (en) 2014-09-25
KR20150143439A (ko) 2015-12-23
RU2015144155A (ru) 2017-04-24
JP2016513677A (ja) 2016-05-16
WO2014152144A1 (en) 2014-09-25
US9670209B2 (en) 2017-06-06

Similar Documents

Publication Publication Date Title
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
PH12016502167A1 (en) Hdl theraphy markers
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
IN2015DN00438A (pt)
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201600589A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
EP2974598A4 (en) COMPOSITION FOR IMPROVING THE EFFECT OF MONOSACCHARIDES IN THE FIGHT AGAINST PLANT DISEASES
BR112015021003A2 (pt) composições e métodos para a produção biológica de isopreno.
CL2015002434A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
GB201303936D0 (en) Methods and Compositions for the Diagnosis of Alzheimers Disease
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
BR112016021648A2 (pt) novos compostos
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
BR112015033069A2 (pt) moduladores de receptor do hormônio de crescimento
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
EA201591399A1 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
PL3041831T3 (pl) Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
IN2014MN01733A (pt)
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
BR112015021271A2 (pt) Agonistas muscarínicos
BR112017028448A2 (pt) análogos de cisteamina resistentes a ado e usos dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]